[Evaluation on impact of hepatitis B vaccine integrated into routine immunization in the areas of Ministry of Health/Global Alliance for Vaccine and Immunization (GAVI) Cooperation Project P.R. China].
OBJECTIVE
To evaluate the impact of hepatitis B vaccination after hepatitis B vaccine integrated into routine immunization in the areas of Ministry of Health/Global Alliance for Vaccine and Immunization GAVI Cooperation Project (MOH/GAVI Coopreation Project).


METHODS
Children born between 2002 and 2005 were selected from 68 counties of GAVI project by multi-stage random sampling method. Demographic information and hepatitis B vaccination history were collected by questionnaire and review of vaccination records, and 2-4ml serum sample was taken for testing of hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (Anti-HBc) and hepatitis B surface antibody (Anti-HBs) by Enzyme Linksed Immunosorbent Assay (ELISA) method.


RESULTS
Coverage of HepB3 and timely birth dose (HepB1) was 80.02% and 60.06% respectively, the younger, the higher. HepB coverage among children born in urban was higher than children born in rural, born in hospital was higher than born at home. The prevalence of HBsAg for children born between 2002-2005 was decreased to <2%.


CONCLUSIONS
HepB has been successfully integrated into routine immunization in GAVI project areas, the immunization coverage was improved dramatically.
Cui
Fu-Qiang
FQ
Department of National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
Gong
Xiao-Hong
XH
Chen
Yuan-Sheng
YS
D002675:Child, Preschool; D002681:China; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D017589:Immunization Programs / Q000379:methods* / Q000458:organization & administration*; D007223:Infant; D008297:Male; D015397:Program Evaluation
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines